COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	12 Months Ended
	May 31, 2016	May 31, 2015
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)	$ 3.00
Stock Issued During Period, Shares, New Issues (in Shares)	333,334
Stock Issued During Period, Value, New Issues	$ 995,978
Royalty Agreements [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Expense	$ 24,000	$ 24,000
Royalty Expense Percentage Of Sales	3.50%	3.20%
Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term Period	5 years
Additional Agreement Term Period	2 years
US FDA [Member] | Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Clearance Fees	$ 1,250,000
Conversion of Stock, Amount Converted	$ 250,000
Shares Issued, Price Per Share (in Dollars per share)	$ 3.00
Conversion of Stock, Shares Issued (in Shares)	83,333
Korean FDA [Member] | Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Expense	$ 7,250,000
Agreement Term Period	5 years
Celtis Pharm Co., Ltd [Member] | Exclusive Marketing License Agreement [Member] | Private Placement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)	$ 3.00
Stock Issued During Period, Shares, New Issues (in Shares)	333,334
Stock Issued During Period, Value, New Issues	$ 1,000,002
Operating Lease Rental [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Lease Initiation Date	Sep. 01, 2009
Lease Expiration Date	Aug. 31, 2016
Operating Leases, Rent Expense, Minimum Rentals	$ 21,000
Operating Leases, Rent Expense, Contingent Rentals	23,637
Security Deposit Liability	22,080
Operating Leases, Rent Expense	235,927	$ 236,154
Operating Lease Rental [Member] | MX [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense	$ 36,234	$ 36,000